---
title: "United States Amino Acid API  Market Research Report 2025-2032"
datePublished: Tue Sep 30 2025 18:28:36 GMT+0000 (Coordinated Universal Time)
cuid: cmg6w58qy000c02lb3py221hk
slug: united-states-amino-acid-api-market-research-report-2025-2032

---

# United States Amino Acid API  Market Research Report 2025-2032

<p><strong>MARKET INSIGHTS</strong></p><p>
</p><p>The United States Amino Acid API market size was valued at USD 1.23 billion in 2024 and is projected to grow from USD 1.31 billion in 2025 to USD 1.98 billion by 2032, exhibiting a CAGR of 5.7% during the forecast period.</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/280291/united-states-amino-acid-api-market">
            https://www.24chemicalresearch.com/download-sample/280291/united-states-amino-acid-api-market</a></b></div><br><p>
</p><p>Amino Acid APIs are pharmaceutical-grade amino acids used as active pharmaceutical ingredients in therapeutic formulations, parenteral nutrition, and biopharmaceutical applications. These building blocks of proteins include essential amino acids like L-Leucine, L-Valine, and L-Isoleucine, along with conditionally essential and non-essential varieties. The market has seen consistent 4-6% annual growth since 2020, with pharmaceutical applications driving 68% of demand as of 2024. Recent FDA approvals for amino acid-based orphan drugs have further stimulated market expansion, with 12 new approvals in 2023 alone.</p><p>
</p><p>Growth drivers include rising chronic disease prevalence, increased adoption of targeted therapies, and expanding applications in cell culture media. The market is also benefiting from technological advancements in fermentation processes, which now account for 45% of production versus traditional extraction methods. Regulatory support for GMP-certified amino acids and growing demand for high-purity (&gt;99%) formulations in biologics manufacturing continue to shape the industry landscape.</p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Rising Demand for Pharmaceutical-Grade Amino Acids in Specialty Medicine</strong></p><p>
</p><p>The United States Amino Acid API market is experiencing robust growth, primarily driven by the escalating demand for high-purity amino acids in specialty pharmaceuticals. With over 45% of novel drug formulations in clinical trials incorporating amino acid-based APIs as of 2024, pharmaceutical companies are increasingly relying on these compounds for their versatility and therapeutic efficacy. The market saw an 18% year-over-year increase in demand for injectable amino acid formulations, reflecting their critical role in parenteral nutrition and critical care medicine. This surge is particularly evident in oncology treatments, where amino acid-drug conjugates accounted for nearly 30% of targeted cancer therapies approved in 2024, showcasing their importance in modern therapeutic approaches.</p><p>
</p><p style="text-align:center"><strong>Accelerated Adoption in Personalized Nutrition and Sports Medicine</strong></p><p>
</p><p>Personalized nutrition represents one of the fastest-growing segments, with branched-chain amino acid (BCAA) consumption in sports nutrition products increasing by 22% annually. The market value attributable to sports nutrition applications reached $280 million in 2024, fueled by consumer awareness and professional athlete endorsements. Clinical studies demonstrating up to 35% faster muscle recovery with optimized amino acid formulations have further propelled adoption. Furthermore, the geriatric nutrition segment contributes significantly, with amino acid-fortified medical foods for age-related muscle wasting generating approximately $150 million in annual sales, expected to double by 2032.</p><p>
</p><p style="text-align:center"><strong>Technological Advancements in Biomanufacturing Processes</strong></p><p>
</p><p>Innovations in microbial fermentation have revolutionized amino acid production, increasing yields by 40-60% while reducing energy consumption. These improvements are critical as the industry moves toward sustainable manufacturing, with 65% of major producers having adopted closed-loop fermentation systems as of 2025. Recent process optimizations have enabled cost reductions of up to 30% for high-purity L-form amino acids, making APIs more accessible for widespread pharmaceutical use. The implementation of continuous manufacturing technologies for amino acid production, now employed by over 15 major facilities, has reduced batch processing times from 72 hours to under 24 hours while improving consistency.</p><p>
</p><p>Regulatory support for advanced manufacturing technologies provides additional momentum. Inspection data shows 90% approval rates for amino acid API facilities implementing Quality by Design (QbD) principles, compared to 65% for conventional facilities, emphasizing the industry's shift toward more sophisticated production methodologies.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Stringent Regulatory Requirements and Compliance Costs</strong></p><p>
</p><p>The amino acid API sector faces substantial regulatory challenges, with compliance costs increasing by 25% annually since 2022. Recent pharmacopeial updates have introduced 38 new testing requirements for amino acid purity profiles, adding approximately $120,000 per batch in analytical costs. These requirements have extended average approval timelines from 8 months to over 14 months for new amino acid API formulations. The complexity is particularly acute for novel synthetic amino acids, where 60% of submissions require multiple review cycles due to characterization challenges.</p><p>
</p><p>Facilities producing multiple amino acid APIs face additional burdens, with cross-contamination prevention measures now accounting for 15-20% of total production costs, up from 8% five years ago. These factors collectively contribute to a 35% longer time-to-market compared to other small molecule APIs, creating significant barriers for market entrants.</p><p>
</p><p style="text-align:center"><strong>Supply Chain Vulnerability for Critical Raw Materials</strong></p><p>
</p><p>Global supply chain disruptions continue to impact amino acid API production, with lead times for fermentation media components extended by 12-16 weeks in 2025 compared to pre-pandemic levels. This volatility has caused spot prices for key precursors like D-glucose and ammonium salts to fluctuate by as much as 80%, forcing manufacturers to maintain 6-9 months of inventory instead of the previous 2-3 month standard. Transportation costs have similarly increased, with refrigerated shipping expenses up 45% year-over-year for temperature-sensitive L-amino acids.</p><p>
</p><p>The market experienced particularly severe shortages of fermentation-derived tryptophan in early 2025, with 40% of pharmaceutical manufacturers reporting delayed production schedules due to limited availability. Inventory management has become increasingly complex, as amino acid stability requirements demand specialized storage conditions that add 18-22% to warehousing costs compared to conventional APIs.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Talent Shortage in Specialized Bioprocessing</strong></p><p>
</p><p>The industry faces a critical shortage of personnel skilled in advanced fermentation and downstream processing, with 35% of amino acid API manufacturers reporting unfilled technical positions as of Q1 2025. This talent gap is particularly acute in analytical method development for chiral purity assessment, where demand outstrips supply by 4:1 according to workforce surveys. The problem is compounded by rapid technological evolution, requiring continuous retraining that costs manufacturers an average of $18,000 per employee annually.</p><p>
</p><p style="text-align:center"><strong>Cost Pressures from Generic Competition</strong></p><p>
</p><p>Established amino acid APIs face intensifying price competition, with average selling prices declining 5-7% annually since 2022 for standard L-amino acids. This erosion primarily affects manufacturers lacking product differentiation, as over 65% of generic amino acid APIs are now purchased through competitive bidding processes. While novel derivatives command premium pricing, they represent less than 15% of total market volume, forcing most producers to operate on shrinking margins despite increasing quality expectations.</p><p>
</p><p>Second-source qualification requirements impose additional burdens, with 70% of large buyers now demanding dual sourcing for critical amino acid APIs, requiring manufacturers to invest in redundant production capabilities without corresponding revenue guarantees.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Expansion in Rare and Modified Amino Acid Therapeutics</strong></p><p>
</p><p>Therapeutic applications for non-proteinogenic amino acids represent a high-growth sector, with market value projected to triple from $185 million in 2025 to over $550 million by 2032. This expansion is driven by advances in structure-activity optimization, with modified amino acids now featured in 28% of new peptide therapeutics in clinical development. Recent successes include D-amino acid-containing antimicrobial peptides demonstrating 10-100x greater stability than conventional formulations.</p><p>
</p><p style="text-align:center"><strong>Biodegradable Polymer Applications</strong></p><p>
</p><p>Amino acid-derived biomaterials are gaining traction in medical devices, with the market for surgical implants incorporating amino acid polymers growing at 24% CAGR. These innovative materials offer superior biocompatibility, with degradation rates that can be precisely tuned from 3 weeks to 12 months by modifying the amino acid composition. Commercialization of these applications could generate an additional $750 million in amino acid API demand by 2030.</p><p>
</p><p>Emerging opportunities in drug delivery are equally promising, with amino acid-functionalized nanoparticles showing up to 80% improvement in tumor targeting efficiency. Clinical trials for these advanced delivery systems have increased by 40% since 2023, signaling strong future demand for specialized amino acid building blocks.</p><p>


<strong>Segment Analysis:</strong>
</p><p>
				<strong>Cystine</strong></p><p>
				<strong>Others</strong>
				</p><p>
				<strong>Topical Formulations</strong></p><p>
				<strong>Others</strong>
			
			
				<strong>Oral Formulations</strong> prevail in the market because of their convenience and broad applicability in patient care.
			
		
	
</p><p>
<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Companies Strive to Strengthen their Product Portfolio to Sustain Competition</strong></p><p>
</p><p>The competitive landscape of the United States Amino Acid API market is semi-consolidated, featuring a mix of large, medium, and small-sized players that drive innovation and supply in this specialized sector. <strong>Thermo Fisher Scientific Inc.</strong> stands out as a leading player, bolstered by its comprehensive product portfolio of high-purity amino acids and robust global presence, particularly strong in North America where it supports pharmaceutical manufacturing and research applications.</p><p>
</p><p><strong>Ajinomoto Bio-Pharma Services</strong> and <strong>Evonik Industries AG</strong> also commanded significant market shares in 2023. Their expansion is fueled by innovative production techniques, such as advanced fermentation processes, and a focus on meeting demands from the pharmaceutical and nutraceutical end-markets, where amino acids serve as critical active ingredients.</p><p>
</p><p>Furthermore, these companies are pursuing aggressive growth strategies, including facility expansions within the U.S., strategic alliances with biotech firms, and launches of new amino acid derivatives tailored for personalized medicine. Such initiatives are poised to substantially increase their market shares through the forecast period of 2024-2032, as the market grows at a steady CAGR of 5.2%.</p><p>
</p><p>Meanwhile, <strong>Merck KGaA</strong> (through Sigma-Aldrich) and <strong>Lonza Group Ltd</strong> are enhancing their positions via substantial R&amp;D investments, often exceeding 10% of revenues annually, along with partnerships for sustainable sourcing and expansions in custom synthesis capabilities. These efforts not only address rising demands for non-animal-derived amino acids but also ensure sustained competitiveness in a market where the pharmaceutical sector accounts for about 70% of the value, with production volumes reaching 85,000 metric tons in 2023.</p><p>
</p><p>The interplay among these players fosters continuous advancements, particularly in branched-chain amino acids (BCAAs) growing at 7% annually and custom derivatives seeing a 25% year-over-year rise in contract services. However, challenges like supply chain vulnerabilities and regulatory compliance continue to shape strategic decisions, pushing firms toward more efficient fermentation technologies, where capital expenditures rose 30% last year. This dynamic environment benefits stakeholders who adapt quickly, positioning the U.S. market for reliable growth amid increasing adoption in healthcare products and medical treatments.</p><p>
<strong>List of Key Amino Acid API Companies Profiled</strong></p><p>
</p><p>Thermo Fisher Scientific Inc. (U.S.)</p><p>Ajinomoto Bio-Pharma Services (Japan/U.S.)</p><p>Sigma-Aldrich Co. LLC (Merck KGaA) (U.S./Germany)</p><p>Bachem Holding AG (Switzerland/U.S.)</p><p>CordenPharma International (Germany/U.S.)</p><p>Evonik Industries AG (Germany/U.S.)</p><p>Pfizer CentreOne (U.S.)</p><p>Lonza Group Ltd (Switzerland/U.S.)</p><p>Catalent Inc. (U.S.)</p><p>AMRI Global (Albany Molecular Research Inc.) (U.S.)</p><p>
</p><p>
<strong>UNITED STATES AMINO ACID API MARKET TRENDS</strong></p><p>
<strong>Growing Demand for Amino Acid Therapies in Chronic Disease Management</strong></p><p>
</p><p>The United States amino acid API market is witnessing significant growth due to increasing applications in chronic disease management. Amino acid-based formulations are gaining traction in neurological disorders, metabolic diseases, and oncology treatments, with the market value projected to expand at a 5.8% CAGR from 2025 to 2032. In 2025, the market is estimated to reach $1.32 billion, with hospital pharmacies accounting for approximately 42% of total distribution. The rise in intravenous amino acid therapies for malnutrition patients has surged by 21% year-over-year in 2024, particularly for geriatric and post-surgical care applications. Over 65% of pharmaceutical manufacturers are now investing in specialized amino acid formulations, indicating strong industry commitment to this therapeutic segment.</p><p>
<strong>Other Trends</strong></p><p>
</p><p><strong>Expansion of Nutraceutical Applications</strong></p><p>
</p><p>The sports nutrition and wellness sectors are driving remarkable demand for purified amino acid APIs, with the U.S. market seeing a 15% annual increase in BCAA (branched-chain amino acid) consumption since 2023. Fitness supplement manufacturers now represent 28% of total amino acid API purchases, with leucine and glutamine formulations showing the highest growth at 18% and 14% respectively. Market analysis reveals that 74% of new product launches in the functional food sector incorporated amino acid fortification in 2024, demonstrating strong crossover potential between pharmaceutical and nutraceutical applications.</p><p>
<strong>Technological Advancements in Amino Acid Production</strong></p><p>
</p><p>Biotechnological innovations are transforming amino acid API manufacturing, with fermentation efficiency improvements reducing production costs by 22% between 2023-2025. Over 40% of U.S. manufacturers have adopted continuous processing technologies, achieving yields improvement of 30-35% compared to batch processing. The industry is witnessing substantial R&amp;D investment in enzymatic synthesis methods, which now account for 38% of new patent applications in the space. These advancements are significantly enhancing the economic viability of amino acid APIs, with purity levels exceeding 99.9% becoming standard in pharmaceutical-grade production.</p><p>

<strong>Regional Analysis: Amino Acid API Market</strong></p><p>

  
    North America
    
      North America stands as the leading market for amino acid active pharmaceutical ingredients (APIs), bolstered by stringent regulatory frameworks from the U.S. Food and Drug Administration (FDA) and Health Canada. The region thrives on a robust pharmaceutical sector, substantial investments in research and development, and the integration of amino acids in advanced drug formulations, nutritional supplements, and biotechnology processes. The United States dominates with approximately 80% of the North American market share, where key applications include treatments for metabolic disorders, protein therapeutics, and personalized medicine, driven by a production volume of around 85,000 metric tons in 2023.
    
  
  
  
    
      Regulatory leadership</p><p>
      The FDA enforces rigorous standards for API purity, efficacy, and safety, ensuring high-quality amino acid products. This compliance fosters steady demand, particularly for pharmaceutical-grade variants used in injectables and oral therapies, while Health Canada's guidelines further align with international norms to support cross-border trade.
    
    
      Market dominance</p><p>
      The U.S. holds the majority of consumption in North America, fueled by established manufacturing hubs and rising needs in biopharmaceuticals. Major players like Ajinomoto and Lonza leverage local facilities to meet demands in sports nutrition and chronic disease management, where amino acids form essential components.
    
    
      Growth drivers</p><p>
      Increasing adoption of amino acid-based therapies in oncology and neurology, alongside biotechnology advancements, propels expansion. Partnerships between pharma firms and API suppliers focus on sustainable fermentation methods, while a 15% rise in personalized medicine applications underscores the role of customized amino acid derivatives.
    
    
      Challenges</p><p>
      Supply chain vulnerabilities and raw material price volatility pose hurdles, compounded by competition from synthetic alternatives. However, ongoing innovations in production efficiency and a shift toward non-animal-derived sources help mitigate these issues, sustaining long-term market resilience.
    
  
</p><p>
</p><p><strong>Europe</strong></p><p>
Europe's amino acid API market is characterized by a strong emphasis on sustainability and innovation, guided by the European Medicines Agency (EMA) and REACH regulations that prioritize environmental and health safety. Countries like Germany and Switzerland lead in production and R&amp;D, with applications spanning pharmaceuticals for amino acid deficiencies and advanced nutraceuticals. The region benefits from a mature biotech ecosystem, where firms invest in green chemistry to produce high-purity APIs like lysine and methionine. However, Brexit has introduced trade complexities, yet intra-EU collaborations continue to drive efficiency. Growth is supported by rising demand for vegan-friendly and ethically sourced amino acids, aligning with consumer preferences for clean-label products. While the market faces pressures from global supply dependencies, strategic initiatives in circular economy practices enhance competitiveness. Overall, Europe's focus on regulatory harmony and technological integration positions it as a key player, with steady expansion anticipated through enhanced cross-border research efforts and adoption in precision medicine.</p><p>
</p><p><strong>Asia-Pacific</strong></p><p>
The Asia-Pacific region emerges as a dynamic hub for amino acid API manufacturing, propelled by rapid industrialization in China, India, and Japan. Vast production capacities and cost-effective operations make it a global supplier, serving pharmaceutical and healthcare sectors with essential amino acids for drug synthesis and supplements. Urbanization and an aging population fuel demand, particularly in treatments for nutritional imbalances and metabolic conditions. While traditional fermentation techniques dominate due to affordability, there's a noticeable transition toward biotech innovations for higher yields and purity. Environmental regulations are tightening, encouraging sustainable practices amid challenges like raw material sourcing fluctuations. Key markets benefit from government incentives for pharma exports, fostering growth in custom API development. Despite infrastructure gaps in some areas, the region's scale and adaptability ensure its pivotal role, with potential for further integration into global supply chains through quality certifications and R&amp;D investments.</p><p>
</p><p><strong>South America</strong></p><p>
In South America, the amino acid API market is steadily developing, with Brazil and Argentina at the forefront amid expanding healthcare infrastructures. Demand stems from growing needs in medicine for protein malnutrition therapies and healthcare products like dietary supplements. Local production is increasing to reduce import reliance, supported by investments in fermentation technologies. However, economic instability and varying regulatory standards across countries slow progress, limiting access to advanced APIs. Opportunities arise from rising middle-class consumption and public health initiatives targeting chronic diseases. While challenges such as currency volatility affect pricing, regional trade agreements promote collaboration, aiding market maturation. Long-term, enhanced biosecurity measures and partnerships with international firms could bolster supply reliability and innovation in this promising yet constrained landscape.</p><p>
</p><p><strong>Middle East &amp; Africa</strong></p><p>
The Middle East and Africa represent an emerging market for amino acid APIs, driven by healthcare modernization in nations like the UAE and South Africa. Applications focus on nutritional therapies and pharmaceuticals addressing deficiencies prevalent in diverse populations. Infrastructure developments and foreign investments are key enablers, though fragmented regulations and limited local manufacturing capabilities hinder full potential. Demand for imported high-quality APIs persists, with growth tied to economic diversification efforts beyond oil dependency. Challenges including geopolitical tensions and supply logistics are offset by initiatives in biotech education and sustainable sourcing. As urbanization accelerates, opportunities in personalized nutrition and telemedicine integration could spur adoption, laying foundations for sustained expansion despite current barriers.</p><p></p><p><strong>Key Report Takeaways</strong></p><p></p><p>
</p><p>
</p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p>
</p><p>This report presents a comprehensive analysis of the United States Amino Acid API market, covering the period from 2024 to 2032. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed Amino Acid API companies and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of United States Amino Acid API Market?</strong></p><p>
</p><p><strong>-&gt;</strong> The United States Amino Acid API market was valued at <strong>USD 1.23 billion in 2024</strong> and is expected to reach <strong>USD 1.98 billion by 2032</strong>.</p><p>
<strong>Which key companies operate in United States Amino Acid API Market?</strong></p><p>
</p><p><strong>-&gt; Key players</strong> include <strong>Ajinomoto Bio-Pharma Services, Sigma-Aldrich Co. LLC (Merck KGaA), Thermo Fisher Scientific Inc., Bachem Holding AG, CordenPharma International, Evonik Industries AG, Pfizer CentreOne, Lonza Group Ltd, Catalent Inc, and AMRI Global (Albany Molecular Research Inc.)</strong>, among others.</p><p>
<strong>What are the key growth drivers?</strong></p><p>
</p><p>-&gt; Key growth drivers include <strong>increasing demand for specialty pharmaceuticals, growing adoption of amino acid-based therapies, and advancements in biotechnology</strong>.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p><strong>-&gt; The United States</strong> dominates the North American market, driven by robust pharmaceutical infrastructure and high demand in medical applications.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include <strong>non-animal-derived amino acids, custom-manufactured derivatives, and adoption in personalized medicine</strong>.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/280291/united-states-amino-acid-api-market">
            https://www.24chemicalresearch.com/reports/280291/united-states-amino-acid-api-market</a></b></div><br>
            <b>Table of Content:</b><p><h2><span style="font-size:16px"><strong>1 STUDY COVERAGE</strong></span></h2><br />
<p>1.1 Amino Acid API  Product Introduction</p><br />
<h2><span style="font-size:16px"><strong>1.2 Market by Type</strong></span></h2><br />
<p>1.2.1 United Statesn Amino Acid API  Market Size Growth Rate by Type, 2019 VS 2023 VS 2030<br /><br />
1.2.2 Glutamate&nbsp;&nbsp; &nbsp;<br /><br />
1.2.3 Lysine<br /><br />
1.2.4 Methionine<br /><br />
1.2.5 Cystine<br /><br />
1.2.6 other<br /><br />
<h2><span style="font-size:16px"><strong>1.3 Market by Application</strong></span></h2><br />
<p>1.3.1 United States Amino Acid API  Market Size Growth Rate by Application, 2019 VS 2023 VS 2030<br /><br />
1.3.2&nbsp;&nbsp; &nbsp;Medicine<br /><br />
1.3.3&nbsp;&nbsp; &nbsp;Healthcare Product<br /><br />
1.4 United States Amino Acid API  Sales Estimates and Forecasts 2019-2030<br /><br />
1.5 United States Amino Acid API  Hydrocephalus Shunts Revenue Estimates and Forecasts 2019-2030<br /><br />
1.6 Study Objectives<br /><br />
1.7 Years Considered</p><br />
<h2><span style="font-size:16px"><strong>2 COMPETITION BY MANUFACTURERS</strong></span></h2><br />
<p>2.1 United States Amino Acid API  Sales by Manufacturers<br /><br />
2.1.1 United States Amino Acid API  Sales by Manufacturers (2019-2024)<br /><br />
2.1.2 United States Amino Acid API  Sales Market Share by Manufacturers (2019-2024)<br /><br />
2.1.3 Top Largest Manufacturers of Amino Acid API  in 2023 in United States<br /><br />
2.2 United States Amino Acid API  Revenue by Manufacturers<br /><br />
2.2.1 United States Amino Acid API  Revenue by Manufacturers (2019-2024)<br /><br />
2.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/280291/united-states-amino-acid-api-market">
            https://www.24chemicalresearch.com/reports/280291/united-states-amino-acid-api-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>